{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:48:39Z","timestamp":1791474519046,"version":"4.3.4"},"reference-count":46,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,4,8]],"date-time":"2027-04-08T00:00:00Z","timestamp":1807142400000},"content-version":"am","delay-in-days":372,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["1R01HL173239-01A1"],"award-info":[{"award-number":["1R01HL173239-01A1"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["1R21HL175174-01A1"],"award-info":[{"award-number":["1R21HL175174-01A1"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015131","name":"Foundation for Sarcoidosis Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015131","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["CHEST"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.chest.2025.09.130","type":"journal-article","created":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:10:05Z","timestamp":1760145005000},"page":"1006-1017","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparative Outcomes and Side Effects of Immunosuppressants and Tumor Necrosis Factor Inhibitors in Sarcoidosis"],"prefix":"10.1016","volume":"169","author":[{"given":"Wen-Cheng","family":"Chao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9477-3837","authenticated-orcid":false,"given":"Shu-Yi","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.chest.2025.09.130_bib1","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.04079-2020","article-title":"ERS clinical practice guidelines on treatment of sarcoidosis","volume":"58","author":"Baughman","year":"2021","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.chest.2025.09.130_bib2","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/MCP.0000000000000715","article-title":"Sarcoidosis epidemiology: recent estimates of incidence, prevalence and risk factors","volume":"26","author":"Arkema","year":"2020","journal-title":"Curr Opin Pulm Med"},{"issue":"6","key":"10.1016\/j.chest.2025.09.130_bib3","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1183\/13993003.01819-2016","article-title":"Assessing the worldwide epidemiology of sarcoidosis: challenges and future directions","volume":"48","author":"Cozier","year":"2016","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.chest.2025.09.130_bib4","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/MCP.0000000000000896","article-title":"The treatment of sarcoidosis: translating the European respiratory guidelines into clinical practice","volume":"28","author":"Judson","year":"2022","journal-title":"Curr Opin Pulm Med"},{"issue":"9","key":"10.1016\/j.chest.2025.09.130_bib5","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/jama.2022.1570","article-title":"Diagnosis and treatment of pulmonary sarcoidosis: a review","volume":"327","author":"Belperio","year":"2022","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.chest.2025.09.130_bib6","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.chest.2024.10.040","article-title":"Sarcoidosis treatment patterns in the United States: 2016-2022","volume":"167","author":"Sangani","year":"2024","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.chest.2025.09.130_bib7","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/MCP.0000000000000078","article-title":"Cytotoxic agents in sarcoidosis: which one should we choose?","volume":"20","author":"Vorselaars","year":"2014","journal-title":"Curr Opin Pulm Med"},{"issue":"5","key":"10.1016\/j.chest.2025.09.130_bib8","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1164\/rccm.202106-1366CI","article-title":"Management of advanced pulmonary sarcoidosis","volume":"205","author":"Gupta","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.chest.2025.09.130_bib9","article-title":"New advances in the management of pulmonary sarcoidosis","volume":"367","author":"Culver","year":"2019","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.chest.2025.09.130_bib10","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/resp.14001","article-title":"Infection risk in sarcoidosis patients treated with methotrexate compared to azathioprine: a retrospective \u2018target trial\u2019 emulated with Swedish real-world data","volume":"26","author":"Rossides","year":"2021","journal-title":"Respirology"},{"issue":"4","key":"10.1016\/j.chest.2025.09.130_bib11","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.chest.2024.11.033","article-title":"Sarcoidosis treatment patterns in the United States: the need for real-world evidence to inform future practice","volume":"167","author":"Rossides","year":"2025","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.chest.2025.09.130_bib12","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/s41584-020-0374-8","article-title":"Mycophenolate mofetil, azathioprine and tacrolimus: mechanisms in rheumatology","volume":"16","author":"Broen","year":"2020","journal-title":"Nat Rev Rheumatol"},{"issue":"12","key":"10.1016\/j.chest.2025.09.130_bib13","article-title":"Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipients","author":"Wagner","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"10.1016\/j.chest.2025.09.130_bib14","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1136\/ard.2010.131995","article-title":"Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial","volume":"69","author":"Houssiau","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"20","key":"10.1016\/j.chest.2025.09.130_bib15","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1056\/NEJMoa1014460","article-title":"Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis","volume":"365","author":"Dooley","year":"2011","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.chest.2025.09.130_bib16","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/annrheumdis-2014-206897","article-title":"Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis","volume":"75","author":"Tamirou","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.chest.2025.09.130_bib17","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1136\/annrheumdis-2012-201338","article-title":"Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry","volume":"72","author":"van Dartel","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.chest.2025.09.130_bib18","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/j.cgh.2016.11.024","article-title":"Comparison of infliximab and adalimumab in biologic-naive patients with ulcerative colitis: a nationwide Danish cohort study","volume":"15","author":"Singh","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.chest.2025.09.130_bib19","doi-asserted-by":"crossref","first-page":"232","DOI":"10.5009\/gnl19433","article-title":"Comparison of long-term outcomes of infliximab versus adalimumab treatment in biologic-naive patients with ulcerative colitis","volume":"15","author":"Lee","year":"2021","journal-title":"Gut Liver"},{"issue":"3","key":"10.1016\/j.chest.2025.09.130_bib20","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1378\/chest.12-1728","article-title":"Methotrexate vs azathioprine in second-line therapy of sarcoidosis","volume":"144","author":"Vorselaars","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.chest.2025.09.130_bib21","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.rmed.2016.04.011","article-title":"Efficacy of adalimumab in sarcoidosis patients who developed intolerance to infliximab","volume":"115","author":"Crommelin","year":"2016","journal-title":"Respir Med"},{"issue":"13","key":"10.1016\/j.chest.2025.09.130_bib22","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1111\/1471-0528.15199","article-title":"Randomised controlled trials\u2014the gold standard for effectiveness research: study design: randomised controlled trials","volume":"125","author":"Hariton","year":"2018","journal-title":"BJOG"},{"issue":"6","key":"10.1016\/j.chest.2025.09.130_bib23","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1378\/chest.12-1920","article-title":"The pros and cons of propensity scores","volume":"142","author":"Streiner","year":"2012","journal-title":"Chest"},{"issue":"8","key":"10.1016\/j.chest.2025.09.130_bib24","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available","volume":"183","author":"Hernan","year":"2016","journal-title":"Am J Epidemiol"},{"issue":"2","key":"10.1016\/j.chest.2025.09.130_bib25","doi-asserted-by":"crossref","DOI":"10.1093\/jamiaopen\/ooad035","article-title":"A global federated real-world data and analytics platform for research","volume":"6","author":"Palchuk","year":"2023","journal-title":"JAMIA Open"},{"issue":"1","key":"10.1016\/j.chest.2025.09.130_bib26","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","article-title":"The central role of the propensity score in observational studies for causal effects","volume":"70","author":"Rosenbaum","year":"1983","journal-title":"Biometrika"},{"issue":"6","key":"10.1016\/j.chest.2025.09.130_bib27","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases","volume":"45","author":"Deyo","year":"1992","journal-title":"J Clin Epidemiol"},{"issue":"8","key":"10.1016\/j.chest.2025.09.130_bib28","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1513\/AnnalsATS.201511-760OC","article-title":"Sarcoidosis in America. Analysis based on health care use","volume":"13","author":"Baughman","year":"2016","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.chest.2025.09.130_bib29","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jdin.2022.07.006","article-title":"The prevalence and geographic distribution of sarcoidosis in the United States","volume":"9","author":"Nam","year":"2022","journal-title":"JAAD Int"},{"issue":"7","key":"10.1016\/j.chest.2025.09.130_bib30","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1016\/j.transproceed.2004.07.057","article-title":"Safety of mycophenolate mofetil versus azathioprine in renal transplantation: a systematic review","volume":"36","author":"Wang","year":"2004","journal-title":"Transplant Proc"},{"issue":"6","key":"10.1016\/j.chest.2025.09.130_bib31","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1007\/s40744-023-00595-5","article-title":"Association between mycophenolate mofetil use and subsequent infections among hospitalized patients with systemic lupus erythematosus: a nested case-control study","volume":"10","author":"Guo","year":"2023","journal-title":"Rheumatol Ther"},{"issue":"8","key":"10.1016\/j.chest.2025.09.130_bib32","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1002\/art.1780340805","article-title":"Methotrexate versus azathioprine in the treatment of rheumatoid arthritis. A forty-eight-week randomized, double-blind trial","volume":"34","author":"Jeurissen","year":"1991","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.chest.2025.09.130_bib33","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jaci.2011.03.024","article-title":"A randomized trial of methotrexate versus azathioprine for severe atopic eczema","volume":"128","author":"Schram","year":"2011","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.chest.2025.09.130_bib34","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1111\/bjd.16240","article-title":"Methotrexate and azathioprine for severe atopic dermatitis: a 5-year follow-up study of a randomized controlled trial","volume":"178","author":"Gerbens","year":"2018","journal-title":"Br J Dermatol"},{"issue":"10","key":"10.1016\/j.chest.2025.09.130_bib35","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1001\/jama.2019.12618","article-title":"Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis: a randomized clinical trial","volume":"322","author":"Rathinam","year":"2019","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.chest.2025.09.130_bib36","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1111\/j.1468-3083.2010.03667.x","article-title":"Efficacy and safety of mycophenolate mofetil vs. methotrexate for the treatment of chronic plaque psoriasis","volume":"24","author":"Akhyani","year":"2010","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.chest.2025.09.130_bib37","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.reuma.2017.07.020","article-title":"Systematic review and meta-analysis of the efficacy and safety of leflunomide and methotrexate in the treatment of rheumatoid arthritis","volume":"15","author":"Alfaro-Lara","year":"2019","journal-title":"Reumatol Clin (Engl Ed)"},{"issue":"10","key":"10.1016\/j.chest.2025.09.130_bib38","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.35950","article-title":"Monotreatment with conventional antirheumatic drugs or glucocorticoids in rheumatoid arthritis: a network meta-analysis","volume":"6","author":"Guski","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"9","key":"10.1016\/j.chest.2025.09.130_bib39","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1007\/s00277-022-04896-7","article-title":"Hematologic side effects of biologics and kinase inhibitors used in rheumatologic diseases: a review of the current evidence","volume":"101","author":"Bhandari","year":"2022","journal-title":"Ann Hematol"},{"issue":"6","key":"10.1016\/j.chest.2025.09.130_bib40","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1007\/s10067-006-0229-y","article-title":"A case report of tumor necrosis factor-alpha antibody-induced thrombocytopenia associated with emerging IgM anticardiolipin antibody in patients with scleroderma overlap\/rheumatoid arthritis","volume":"26","author":"Hamaguchi","year":"2007","journal-title":"Clin Rheumatol"},{"issue":"4","key":"10.1016\/j.chest.2025.09.130_bib41","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/j.1365-2036.2012.05189.x","article-title":"Review article: non-malignant haematological complications of anti-tumour necrosis factor alpha therapy","volume":"36","author":"Bessissow","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"issue":"11","key":"10.1016\/j.chest.2025.09.130_bib42","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1007\/s10067-016-3351-5","article-title":"Premedication prevents infusion reactions and improves retention rate during infliximab treatment","volume":"35","author":"Bartoli","year":"2016","journal-title":"Clin Rheumatol"},{"issue":"2","key":"10.1016\/j.chest.2025.09.130_bib43","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1002\/art.21568","article-title":"Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy","volume":"54","author":"Wolfe","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.chest.2025.09.130_bib44","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.cgh.2008.03.014","article-title":"Efficacy and safety of tumor necrosis factor antagonists in Crohn\u2019s disease: meta-analysis of placebo-controlled trials","volume":"6","author":"Peyrin-Biroulet","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.chest.2025.09.130_bib45","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1136\/annrheumdis-2011-201108","article-title":"Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register","volume":"72","author":"Galloway","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.chest.2025.09.130_bib46","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.28045","article-title":"Strategies to turn real-world data into real-world knowledge","volume":"4","author":"Hong","year":"2021","journal-title":"JAMA Netw Open"}],"container-title":["CHEST"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369225055059?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369225055059?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T09:38:30Z","timestamp":1775641110000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369225055059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0012369225055059"],"URL":"https:\/\/doi.org\/10.1016\/j.chest.2025.09.130","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative Outcomes and Side Effects of Immunosuppressants and Tumor Necrosis Factor Inhibitors in Sarcoidosis","name":"articletitle","label":"Article Title"},{"value":"CHEST","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2025.09.130","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American College of Chest Physicians. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}